NDA 18289, held by Ge Healthcare. Iodohippurate Sodium I-123.
As of Nov 13, 2026, NDA 18289 (Nephroflow), held by Ge Healthcare, was first approved by FDA on Dec 28, 1984, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 28, 1984 | Original applicationNew molecular entity · Standard review | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Nephroflow1mCi/ML · injectable;injection | Iodohippurate Sodium I-123 | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
